Twist Bioscience (TWST) Change in Accured Expenses (2017 - 2026)

Twist Bioscience has disclosed Change in Accured Expenses across 10 years of filings, most recently posting $35.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 537.25% year-over-year to $35.2 million; the TTM figure through Mar 2026 stood at $38.1 million (up 15699.59% YoY), while the FY2025 annual figure was $6.6 million, down 16.04% from the prior year.
• Change in Accured Expenses rose to $35.2 million in Q1 2026, from -$12.4 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for TWST reached as high as $35.2 million in Q1 2026 and fell as low as -$12.4 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is -$456000.0 (2023), against an average of $2.7 million.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses soared 2232.46% — and 2025, when it tumbled 1969.22%.
• A 5-year view of Change in Accured Expenses shows it stood at -$3.7 million in 2022, then slumped by 36.65% to -$5.1 million in 2023, then jumped by 88.16% to -$601000.0 in 2024, then plunged by 1969.22% to -$12.4 million in 2025, then soared by 383.28% to $35.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $35.2 million, -$12.4 million, and $11.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.